Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer

• DOI: 10.1001/jamanetworkopen.2022.4637
• Publication Date: 2022-03-29T19:06:02Z
• Authors: Na Zhuo; Chang Liu; Qi Zhang; Jian Li; Xiaotian Zhang; Jifang Gong; Ming Lu; Zhi Peng; Jun Zhou; Xicheng Wang; Xi Jiao; Yujiao Wang; Yanni Wang; Mengting Gao; Lin Shen; Zhihao Lu
• Keywords: Univariate analysis

With the expanding use of immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer, occurrence acquired resistance (AR) has gradually emerged. However, progression patterns and survival patients with AR to ICIs are still unknown.To explore characteristics prognosis after ICI therapy advanced GI cancer.This cohort study screened cancer treated between January 14, 2016, December 31, 2020, at Peking University Cancer Hospital. Initial response was defined as complete response, partial or stable disease longer than 6 months assessed by Response Evaluation Criteria Solid Tumors version 1.1. Progression also based on death initial AR. Oligoprogression 2 more sites progression. The current status its were evaluated. site subsequent management assessed. Data analyzed from June August 2021.Patients mono-ICI combination therapy.Kaplan-Meier analyses log-rank tests conducted for overall analyses. Univariate multivariate Cox determine prognostic implications each variable.Of 1124 who received ICIs, 373 (33.2%) (282 men [75.6%]; median [IQR] age, 62 [54-68] years) achieved an 173 (46.4%) (137 [79.2%]; 61 [54-67] developed Almost all (167 [96.5%]) within 24.0 months. most commonly oligoprogression (122 [70.5%]) rather polymetastatic (38 [22.0%]) associated a good (38.5 vs 14.0 months; hazard ratio, 0.37; 95% CI, 0.18-0.74; P < .001). Lymph nodes (101 [58.4%]) appeared be common Management mainly systemic (96 [55.5%]).Oligoprogression pattern progression, lymph susceptible Further will needed favorable